Canaccord analyst Edward Nash raised the firm’s price target on Corcept Therapeutics to $37 from $35 and keeps a Buy rating on the shares. The firm said they reported financial results and business highlights for 3Q23, and sales of Korlym showed a 22% YoY growth of $123.6M in the quarter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CORT:
- Corcept Therapeutics price target raised to $34 from $32 at H.C. Wainwright
- Corcept increases FY23 revenue view $470M-$480M from from $455M – $470M
- Corcept Therapeutics reports Q3 EPS 28c, consensus 22c
- Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics appoints Monica Tellado as president, emerging markets